Avestria Ventures
VC Fund
Lafayette, United States
Avestria Ventures is an investment firm that focuses on women's health and female-led life science and healthcare companies. They define women's health as illnesses that affect women exclusively (such as menopause), differently (such as cardiovascular disease), or disproportionately (such as Alzheimer's).
- Total investments:
- 24
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Avestria Ventures invests in
Stages Avestria Ventures invests in
Countries Avestria Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 12 (50%)
- Medical 11 (46%)
- Medical Device 6 (25%)
- Biotechnology 4 (17%)
- Women's 3 (13%)
Stage
- Series A 6 (25%)
- Seed 3 (13%)
- Series B 3 (13%)
- Series C 3 (13%)
- Venture - Series Unknown 2 (8%)
Country
- United States 15 (63%)
- France 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Linda Greub
Co-founder & Managing Partner
|
Co-founder & Managing Partner | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Curio is a developer of reliable technology and an analytics engine intended for the management of women's health. The corporate platform intends to provide individualized, research-based care for a range of problems affecting women's health, enabling consumers' behavioral and physical healthcare demands through the development oftailored therapies. It is dedicated to giving women of various ages and physiological problems contextualized care. | Venture - Series Unknown / Aug 28, 2024 | |
|
|
Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening. | $26M / Series A / Jul 17, 2024 | |
|
|
Axena Health is a women-led company dedicated to improving the lives of women with pelvic floor disorders by leveraging the power of digital technology. | $9.4M / Series A / Jun 04, 2024 | |
|
|
AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience.AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. AblaCare's procedure is donetransvaginally, under ultrasound guidance, and does not require general anesthesia. The technique can be performed in the clinic setting using the same minimally invasive access commonly used by fertility physicians for IVF. | $24.8M / Series B / May 13, 2024 | |
|
|
Mae is a maternal health platform that connects expectant mothers with critical resources to drive positive pregnancy outcomes. | Seed / May 07, 2024 | |
|
|
Midi Health provides virtual healthcare services focused on midlife women’s health, especially around hormonal changes such as perimenopause and menopause, through personalized care plans delivered by clinicians trained in these areas. Its services include telehealth consultations that can integrate prescription support, supplements, lifestyleguidance, and symptom-specific treatments to address issues like weight, mood, sleep, and sexual wellness. Midi Health also offers tailored support protocols that consider an individual’s health history and goals to guide ongoing care. Its platform makes care accessible online and works with insurance for coverage of visits and prescriptions. The company additionally offers targeted supplements designed to complement its clinical care approach. | $63M / Series B / Apr 24, 2024 | |
|
|
Avation Medical is pioneering new platforms for wearable nerve stimulation systems. They believe empowering patients to be in control of their therapies will allow for more personalized and custom care. That's why at Avation Medical, they are re‑imagining neuromodulation by developing patient‑centric solutions based on powerful, proven, smarttechnologies.Avation Medical transforms the neuromodulation market to elevate care for patients with chronic conditions. | $22M / Series C / Feb 01, 2024 | |
|
|
Axena Health is a women-led company dedicated to improving the lives of women with pelvic floor disorders by leveraging the power of digital technology. | $1.8M / Private Equity / Aug 08, 2023 | |
|
|
Axena Health is a women-led company dedicated to improving the lives of women with pelvic floor disorders by leveraging the power of digital technology. | $1.8M / Venture - Series Unknown / Aug 08, 2023 | |
|
|
AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $5M / Seed / Sep 13, 2022 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Avestria Ventures invest in?
Avestria Ventures invests primarily in Health Care, Medical and Medical Device startups, most often at Series A and Seed stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Avestria Ventures?
Public channels for Avestria Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Avestria Ventures?
The team at Avestria Ventures includes Linda Greub (Co-founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!